CWS
AXDX

Confluence Wealth Services’s Accelerate Diagnostics AXDX Stock Holding History

Confluence Wealth Services’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6
Closed – – 321
2021
Q4 		$0 Buy
+6
New +$334 ﹤0.01% 1227

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Confluence Wealth Services's AXDX Position: Q1 2022 in Review

Confluence Wealth Services sold out of Accelerate Diagnostics (AXDX) in Q1 2022, closing a stake of 6 shares.

Confluence Wealth Services first reported a position in AXDX in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 106 funds tracked by Wall St. Rank hold AXDX as of Q1 2022.

  • Confluence Wealth Services reported no remaining Accelerate Diagnostics position as of Q1 2022 after selling out during the quarter.
  • Confluence Wealth Services sold 6 Accelerate Diagnostics shares in Q1 2022.
  • Confluence Wealth Services first reported a position in Accelerate Diagnostics in Q4 2021 and held it in 1 quarter.
  • Confluence Wealth Services's Accelerate Diagnostics position peaked at $0 in Q4 2021.
  • 106 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2022.

Based on Confluence Wealth Services's 13F filing for Q1 2022, filed 26 Apr 2022.